Beam Therapeutics Files 8-K on Operations, Financial Condition

Ticker: BEAM · Form: 8-K · Filed: Jan 8, 2024

Complexity: simple

Sentiment: neutral

Topics: corporate-update, financial-disclosure, regulation-fd

TL;DR

**Beam Therapeutics just dropped an 8-K, likely signaling new financial or operational updates are coming.**

AI Summary

Beam Therapeutics Inc. filed an 8-K on January 8, 2024, to report on its 'Results of Operations and Financial Condition,' 'Regulation FD Disclosure,' and 'Other Events.' This filing indicates that the company is providing an update on its financial status and other significant developments, likely ahead of a public announcement or investor presentation. For investors, this matters because it signals that new, potentially impactful information about Beam's financial health or strategic direction is being disclosed, which could influence the stock price (BEAM).

Why It Matters

This filing indicates that Beam Therapeutics is providing an update on its financial performance and other key events, which could contain material information for investors.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure of an upcoming event, not an event itself, so it carries minimal direct risk.

Analyst Insight

A smart investor would monitor Beam Therapeutics' news releases and investor relations pages closely for the actual content of the 'Results of Operations and Financial Condition' and 'Other Events' that this 8-K foreshadows, as these will contain the material information.

Key Players & Entities

Forward-Looking Statements

FAQ

What is the primary purpose of this 8-K filing by Beam Therapeutics Inc.?

The primary purpose of this 8-K filing by Beam Therapeutics Inc. is to report on 'Results of Operations and Financial Condition,' 'Regulation FD Disclosure,' and 'Other Events' as of January 8, 2024.

What is the trading symbol and exchange for Beam Therapeutics Inc. common stock?

The trading symbol for Beam Therapeutics Inc. common stock is BEAM, and it is registered on the Nasdaq Global Select Market.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing was on January 8, 2024.

What is the business address of Beam Therapeutics Inc. as stated in the filing?

The business address of Beam Therapeutics Inc. is 238 Main Street, Cambridge, Massachusetts, 02142.

Is Beam Therapeutics Inc. considered an emerging growth company according to this filing?

The filing indicates with an unchecked box that Beam Therapeutics Inc. is NOT simultaneously satisfying the filing obligation of the registrant under any of the provisions related to an emerging growth company, implying it is not an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Filing Stats: 1,430 words · 6 min read · ~5 pages · Grade level 15.5 · Accepted 2024-01-08 06:55:18

Key Financial Figures

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. Although it has not finalized its full financial results for the fourth quarter and fiscal year ended December 31, 2023, Beam Therapeutics Inc. (the “Company”) announced in a press release on January 8, 2024 that it estimates that it had cash, cash equivalents and marketable securities of approximately $1.2 billion as of December 31, 2023. The information contained in this Item 2.02 regarding the Company’s estimated cash balance as of December 31, 2023 is preliminary, unaudited and is subject to completion of the Company’s financial statement closing procedures. This estimate also does not present all information necessary for an understanding of the Company’s financial condition as of December 31, 2023 and its results of operations for the three months and year ended December 31, 2023. Accordingly, undue reliance should not be placed on this preliminary estimate. The information in this Item 2.02 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”) or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 8, 2024, the Company updated its corporate presentation that it intends to use in connection with presentations at conferences and meetings, including an investor presentation at the 42 nd Annual J.P. Morgan Healthcare Conference on January 8, 2024. The slides from the Company’s corporate presentation are furnished as Exhibit 99.1 to this Current Report on Form 8-K and are incorporated herein by reference. The information in this Item 7.01 (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filling.

01 Other Events

Item 8.01 Other Events. On January 8, 2024, the Company issued a press release announcing progress across its base editing portfolio and outlining key anticipated milestones. The full text of the press release is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained on the website referenced in the press release is not incorporated herein. Cautionary Note Regarding Forward-Looking Statements

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Beam Therapeutics Inc. Corporate Presentation 99.2 Press Release dated January 8, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BEAM THERAPEUTICS INC. Date: January 8, 2024 By: /s/ John Evans John Evans Chief Executive Officer

View on Read The Filing